184426-82-2

Upstream product

• 611-71-2 MANDELIC ACID 
• 340188-51-4 (R)-2-amino-2-(4-bromophenyl)-propionic acid ethyl ester 
• 184427-33-6 (R,S)-2-amino-2-(4-bromophenyl)-propionic acid ethyl ester 
• 99-90-1 para-bromoacetophenone 
• 72408-57-2 (R,S)-2-amino-2-(4-bromophenyl)-propionic acid 
• 6320-50-9 (R,S)-4-(4-bromophenyl)-4-methyl-2,5-dioxoimidazolidine 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 177563-40-5 3-{2-[4-(R)-(4-aminoiminomethyl-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl]acetylamino}-3-(S)-phenylpropionic acid ethyl ester 
• 177563-40-5 3-{2-[4-(R)-(4-aminoiminomethyl-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl]acetylamino}-3-(R)-phenylpropionic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold

Antagonists of the platelet fibrinogen receptor (GP IIb/IIIa receptor) are expected to be a promising new class of antithrombotic agents. The binding of fibrinogen to the fibrinogen receptor depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif. Structural modifications of the RGDS lead have led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist 44 (S 1197). Compound 44 inhibited, in a dose dependent and reversible manner, human and dog platelet aggregation as well as 125I-fibrinogen binding to ADP-activated human gel filtered platelets and isolated GP IIb/IIIa with Ki values of 9 nM and 0.17 nM, respectively. A pharmacophore mapping procedure with QXP and a 3D-QSAR analysis applying the GRID/GOLPE methodology yielded a stable, rather predictive model and revealed structural features which are important for binding. Hydrophobic substitutions both at the hydantoin nucleus and at the C-terminus increase the affinity toward the fibrinogen receptor. The crystalline ethyl ester prodrug 48 (HMR 1794) is an orally active antithrombotic agent which is a promising drug candidate for the treatment of thrombotic diseases in humans.

Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them

The present invention relates to hydantoin derivatives of the formula I STR1 and which are intermediates for the preparation of pharmaceutical active compounds, their preparation and their use in the preparation of the active compounds.